Clinical trials are imperative for testing the efficacy of novel drugs and therapies. It has been used by pharmaceutical and biopharmaceutical sectors for formulating new medicines to combat the onset of chronic diseases. Customized medicines can be prepared according to results gained from the study. The global clinical trials market report by Market Research Future (MRFR) contains drivers, opportunities, and challenges compiled by notable analysts using proprietary research methodologies.
The global clinical trials market is projected to expand at 5.7?GR from 2017 to 2023 (forecast period). Global use of clinical trials for development of novel drugs is the primary driver of the market. Emergence of theranostics combined with demand for contract research organizations (CROs) are other drivers of the market. Development of drugs for orphan diseases and large offering of services by CROs for numerous regions can bode well.
Get Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/7787
Massive demand for generic drugs due to expensive nature of commercial drugs are likely to bolster the demand in the global clinical trials market. Collaborations between major pharmaceutical companies can cover the gap of the number of medicines being available to the masses and fuel the market growth.
Competition Outlook
Paraxel International Corporation, Eli Lilly and Company, SGS SA, ICON plc, Laboratory Corporation of America, Novo Nordisk A/S, Charles River Laboratories, Quintiles IMS, Pfizer, and Clinipace are prominent names in the global clinical trials market report.
Segmentation
The global clinical trials market is segmented based on phase, study design, indication and end users.
Regional Analysis
The Americas, the Middle East & Africa, Europe, and Asia Pacific (APAC) are regions considered in the global clinical trials market report.
The Americas are touted to dominate the global market due to a huge patient pool, large number of pharma companies, and ample funding to fuel research and development. In addition, the rising number of cases of patients with cancer, diabetes, and chronic diseases can boost the clinical trials market demand. According to the National Cancer Institute, nearly 64,000 cases of kidney cancer are expected to be registered in the U.S.
Europe is expected to be the second biggest region for the global clinical trials market due to increasing prevalence of new diseases and high R&D budget allocated for research purposes. Introduction of new regulations for clinical trials can boost innovation and development of new drugs.
Get Access Full Report @ https://www.marketresearchfuture.com/reports/clinical-trials-market-7787
The APAC region can grow at a rapid pace due to ongoing government support for R&D hubs, rising emphasis for development of drugs for rare diseases, and a large patient pool. Low operational costs and lax tax policies are expected to lead to inflow of investment by global groups in the region.
On the other hand, the MEA region possesses latent potential owing to large healthcare expenditure of economies of Kuwait, Qatar, and Saudi Arabia.
Industry News
Research funding is imperative to the functioning of clinical trials. In 2019, the U.S. Food and Drug Administration (FDA) has awarded 12 clinical trials more than USD 15 million in funds to further the research and testing of drugs for rare diseases.
About Market Research Future:
Market Research Future (MRFR) team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.